Cellectar Biosciences, Inc.

News, Media & IR

Latest News

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

View All News
Latest Presentation
April 26, 2024

Corporate Presentation - April 2024
View Presentation

Investor Relations

View Investor Relations

Latest News List

View all news

Latest News

Latest News

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

View All News
Latest Event
Mar 27, 2024 • 8:30am EDT

Fourth Quarter and Year End 2023 Earnings Call

View All Events

Posters & Publications

Iopofosine I-131 treatment in late-line patients with relapsed/ refractory multiple myeloma post anti-BCMA immunotherapy

Targeted Delivery Platform, Iopofosine I 131

USING TARGETED RADIOTHERAPY IN HIGHLY REFRACTORY MULTIPLE MYELOMA: IOPOFOSINE I 131

SNMMI Conference 2023

Targeted Delivery Platform, Iopofosine I 131

Moving Beyond Solid Tumors: A Novel Radiotherapy in Hematologic Cancers

13th Annual World ADC Conference

Targeted Delivery Platform, Iopofosine I 131

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 CLOVER-1 Trial

Sikander Ailawadhi, MD, Patrick Stiff, MD, Emad Ibrahim, MBBCh, MD, Damian J. Green, MD, Brea Lipe, MD, Elizabeth H. Cull, MD, Natalie S. Callander, MD, John Friend, MD, Jarrod Longcor and Kate Oliver, BS

Targeted Delivery Platform, Iopofosine I 131, PDCs

Treatment Free Remission (TFR) and Overall Response Rate (ORR) Results in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia (WM) Treated with CLR 131

S Ailawadhi2, A Chanan Khan2 , J Peterson2, J Longcor1, K Oliver1, M Brown1, J Friend1 , DJ Green3

Iopofosine I 131

Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical

Ankita Shahi , Gerald E. Weiss , Saswati Bhattacharya , Dana C. Baiu , Roberta Marino , Taner Pula , Natalie S. Callander , Fotis Asimakopoulos & Mario Otto (2021)

Targeted Delivery Platform, Iopofosine I 131, CLR1404

Targeted Treatment Supplemental Document

Ankita Shahi1#, Gerald E. Weiss1#, Saswati Bhattacharya2 , Dana C. Baiu3 , Roberta Marino4 , Taner Pula5 , Natalie S. Callander2 , Fotis Asimakopoulos2,6, and Mario Otto1

Targeted Delivery Platform, Iopofosine I 131, CLR1404

CLR 131 in Patients with Relapsed or Refractory Pediatric Malignancies

Puccetti D, Otto M, Morgenstern D,DeSantes K,Cho SY, Hall L, Oliver K, Longcor J

Iopofosine I 131

ACR Annual Meeting Presentation

CLR 131 Demonstrates 100% Overall Response Rate in Relapsed or Refractory Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM): Initial Results from Ongoing Phase 2 trial, CLOVER-1 Study

S. Ailawadhi1, J. Longcor2, K. Oliver2, I. Grachev2

Iopofosine I 131

Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (R/R DLBCL)

J. Longcor1, K. Oliver1, J. Friend1, N. Callander2

Iopofosine I 131

CLR 2000045, a lipid raft targeted phospholipid-drug conjugate, shows potent activity against multiple breast cancer models including triple negative breast cancer

Longcor J, Hoover R, Pinchuk A

Targeted Delivery Platform, PDCs

Fractionated Dosing of CLR 131 in Patients With Relapsed or Refractory Multiple Myeloma (Rrmm)

Iopofosine I 131

CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors

Longcor J, Hoover R, Pinchuk A

Targeted Delivery Platform, PDCs, PLEs

Phospholipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy.

Longcor J, Hoover R, Pinchuk A

Targeted Delivery Platform, PDCs, PLEs

CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Iopofosine I 131

Preclinical pharmacokinetics and dosimetry studies of [124I/131I]-CLR1404 for treatment of pediatric solid tumors in murine xenograft models

Ian R Marsh

Targeted Delivery Platform, Iopofosine I 131, CLR 124, CLR1404

Efficacy of fractionated injections of CLR 131 in an OPM-2 SCID nude mouse model

Longcor J Friend J

Iopofosine I 131

Combining internal delivery of radiation via CLR1404 with external beam radiation in head and neck cancer

Harari, Paul

Iopofosine I 131, CLR 124

Targeted molecular radiotherapy of pediatric solid tumors using a radioiodinated alkyl-phospholipid ether analog

Baiu, D Otto, M

PLEs

Phospholipid drug conjugates show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy

Longcor J Hoover R

PDCs

The Phospholipid Ether Analog CLR 127 Delays Radiation-induced dsDNA Damage Repair in Pediatric and Adult Solid Tumors

AACR Poster Presentation - UW - October 2017

Targeted Delivery Platform

Efficacy of a repeat dose injection of CLR 131 (I-131-CLR1404) in U87-MG tumor bearing athymic nude mice. (ASCO 2017 abstract)

Oliver K Kandela I

Iopofosine I 131

Efficacy of a single dose injection of CLR 131 (1-131-CLR1404) in a Caki-2 athymic nude mouse model (ASCO 2017 abstract)

Longcor J Kandela I

Iopofosine I 131

Impact of PET and MRI threshold-based tumor volume segmentation on targeted radionuclide therapy patient-specific dosimetry using CLR1404

Besemer, Abigail Bednarz, Bryan

CLR1404

PET/CT Imaging of the Alkylphosphocholine Analog 124I-CLR1404 in High and Low-Grade Brain Tumors

Hall, Lance Kuo, John

CLR 124

Efficacy of repeated injections of CLR 131 (I-131-CLR1404) in a MES SA/Dx5 athymic nude mouse model. (ASCO 2017 abstract)

Oliver K Kandela I

Iopofosine I 131

Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood−Brain Barrier Model

Clark, Paul Shusta, Eric

PLEs

CLR1404, a Tumor-selective Alkyl Phosphocholine Analog, Increases Radiation Sensitivity in Solid Tumors [poster presentation]

Elsaid, M.Y. Otto, Mario

CLR1404

A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies

Lubner, Sam Liu, Glenn

Iopofosine I 131

Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma

Marino, Roberta Otto, Mario

CLR1404

Therapeutic combination of radiolabeled CLR140 with external beam radiation in head and neck cancer model systems

Morris, Zachary Harari, Paul

CLR1404

Fluorescent Cancer-Selective Alkylphosphocholine Analogs for Intraoperative Glioma Detection

Neurosurgery V76, Issue 2, pp. 115-124 -February 2015 - A Peer Reviewed Publication

CLR 1502

Phospholipid Ether Analogs for the Detection of Colorectal Tumors

PLOS ONE V9, Issue 10 - October, 2014 - Peer Reviewed Publication

CLR 1502

A novel "diapeutic" molecular imaging agent for combined oncologic diagnosis and therapy in a broad spectrum of human cancers: Preliminary clinical experience with CLR1404

American Society of Clinical Oncology (ASCO) 2014 Annual Meeting Oral Presentation - Pickhardt - UW - June 2014

Targeted Delivery Platform, CLR 124

American Society of Clinical Oncology (ASCO) 2014 Annual Meeting Oral Presentation - Pickhardt - UW - June 2014

American Society of Clinical Oncology (ASCO) 2014 Annual Meeting Oral Presentation - Pickhardt - UW - June 2014

Iopofosine I 131

American Society of Clinical Oncology (ASCO) 2014 Annual Meeting Poster - Lubner - UW - June 2014

American Society of Clinical Oncology (ASCO) 2014 Annual Meeting Poster - Lubner - UW - June 2014

Iopofosine I 131

A phase 1 study of phospholipid ether [131I]-CLR1404 in patients with advanced solid tumors. (ASCO abstract)

Lubner, Sam Liu, Glenn

Iopofosine I 131

A Phase 1 Study of 131I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety

Grudzinski Joseph Weichert, Jamey

Iopofosine I 131

Cancer-Targeted Diapeutics: Radioiodinated Phospholipid Ether Analogs for Broad-Spectrum Imaging and Therapy

EMIT: Targeted Radiotherapy Oral Presentation - Pazoles - Novelos - January 2013

Targeted Delivery Platform, Iopofosine I 131, CLR 124, CLR 1502

Molecular Diapeutics: Phospholipid Ether Analogs as Broad-Spectrum Cancer and Cancer Stem Cell Detection and Treatment

Imaging in 2020 Oral Presentation - Weichert - UW - October 2012

Targeted Delivery Platform, Iopofosine I 131, CLR 124, CLR 1502

Relative Biodistribution and Tumor Uptake of I-131-CLR1404, in Human Subjects with Advanced Colon Cancer

WMIC Poster Presentation - Liu - UW - September 2012

Targeted Delivery Platform, Iopofosine I 131, CLR 124

Relative Biodistribution and Tumor Uptake of I-124-CLR1404, in Humans with Non-Small Cell Lung Cancer

WMIC Poster Presentation - Traynor - UW - September 2012

Targeted Delivery Platform

First in Human Use of I-124-CLR1404, PET/CT in Primary and Metastatic Brain Tumors

WMIC Poster Presentation - Weichert - UW - September 2012

Targeted Delivery Platform, CLR 124

The novel phospholipid ether analog CLR1404 decreases glioblastoma stem cell proliferation, suppresses GBM growth, and improves survival

AACR Poster Presentation - Kuo - UW - April 2012

Targeted Delivery Platform

I-131-CLR1404 and CLR1404: Broad spectrum, cancer-targeted molecular radio- and chemotherapeutic phospholipid ether analogs

AACR Poster Presentation - Weichert - UW - April 2012

Targeted Delivery Platform, Iopofosine I 131

I-124-CLR1404 and I-131-CLR1404: Broad spectrum diapeutic agents for cancer cell-targeted PET imaging and molecular radiotherapy

AACR Poster Presentation - Weichert - UW - April 2012

Targeted Delivery Platform, Iopofosine I 131, CLR 124

Fluorescent Alkyl Phospholipid Analogs for Fluorescence Imaging of Tumors in vitro and in vivo

WMIC Poster Presentation - Weichert - UW - September 2009

Targeted Delivery Platform, CLR 1502

Synthesis and Structure-Activity Relationship Effects on the Tumor Avidity of Radioiodinated Phospholipid Ether Analogues

Journal of Medicinal Chemistry V49, pp. 2155-2165 - April, 2006 - Peer Reviewed Publication

Targeted Delivery Platform, Iopofosine I 131, CLR 124

Tumor-specific alkylphosphocholine analogs were evaluated as imaging and therapy agents in patients and in animal models of human cancer.

Alkylphosphocholine Analogs for Broad Spectrum Cancer Imaging and Therapy

Targeted Delivery Platform

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.